ORIGINAL ARTICLE
High-grade non-small cell lung carcinoma: a comparative analysis of the phenotypic profile in small biopsies with the corresponding postoperative material
1
Department of Pathomorphology, Medical University of Gdañsk, Poland
2
Laboratory of Cell Biology, Department of Medical Biotechnology, Intercollegiate Faculty of Biotechnology,
University of Gdañsk and Medical University of Gdañsk, Poland
Submission date: 2018-08-27
Final revision date: 2018-11-04
Acceptance date: 2018-12-23
Publication date: 2019-04-01
Pol J Pathol 2019;70(2):100-108
KEYWORDS
TOPICS
ABSTRACT
The most recent classification of the lung cancer expanded the diagnostic criteria of its histological subtypes and included its immunophenotypic profile. We performed the study to compare the reliability of selected markers in high-grade non-small cell lung carcinoma (NSCLC) in the oligobiopsies with the matched postoperative samples. We evaluated expression of p40, p63, TTF1, cytokeratin 5/6, cytokeratin 7, napsin A, desmoglein 3, desmocollin 3 and mucin secretion as detected by mucicarmine staining.
The study cohort included 123 cases of poorly-differentiated NSCLC. The tissue oligobiopsy material was available in 38 cases. Tissue microarrays (TMAs) from all postoperative cases were constructed.
Comparing the immunophenotype between postsurgical samples and oligobiopsies we found an almost perfect agreement for most of performed IHC reactions. The highest concordance of results was found for desmoglein 3, CK7, and p40, whereas the lowest – for desmocollin 3.
Immunoprofile of the oligobiopsies corresponded well to that in the resection specimens. The most useful markers in poorly differentiated ADs are: TTF1 and napsin A, and for non-keratinizing SCCs: p40, p63, CK5/6 and desmoglein 3.
The study cohort included 123 cases of poorly-differentiated NSCLC. The tissue oligobiopsy material was available in 38 cases. Tissue microarrays (TMAs) from all postoperative cases were constructed.
Comparing the immunophenotype between postsurgical samples and oligobiopsies we found an almost perfect agreement for most of performed IHC reactions. The highest concordance of results was found for desmoglein 3, CK7, and p40, whereas the lowest – for desmocollin 3.
Immunoprofile of the oligobiopsies corresponded well to that in the resection specimens. The most useful markers in poorly differentiated ADs are: TTF1 and napsin A, and for non-keratinizing SCCs: p40, p63, CK5/6 and desmoglein 3.
REFERENCES (36)
1.
Islami F, Torre LA, Jemal A. Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res 2015; 4: 327-338.
2.
Soda M, Choi YL, Enomoto M, et al. Identification of the transforming eml4-alk fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-563.
3.
Azzoli CG, Baker S Jr, Temin S, et al. American society of clinical oncology clinical practice guideline update on chemotherapy for stage iv non-small-cell lung cancer. J Clin Oncol 2009; 27: 6251-6266.
4.
Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated egfr. New Engl J Med 2010; 362: 2380-2388.
5.
Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced egfr mutation-positive non-small-cell lung cancer (eurtac): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
6.
Shames DS, Wistuba II. The evolving genomic classification of lung cancer. J Pathol 2014; 232: 121-133.
7.
Travis WD, Brambilla E, Burke AP, et al. WHO classification of tumours of the lung, pleura, thymus and heart. IARC 2015.
8.
Travis WD, Brambilla E, Nicholson AG, et al. The 2015 world health organization classification of lung tumors impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015; 10: 1243-1260.
9.
Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
10.
Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-285.
11.
Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of lung cancer in small biopsies and cytology implications of the 2011 international association for the study of lung cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med 2013; 137: 668-684.
12.
Rekhtman N, Ang DC, Sima CS, et al. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 2011; 24: 1348-1359.
13.
Kadota K, Nitadori JI, Rekhtman N, et al. Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysis. Am J Surg Pathol 2015; 39: 1170-1180.
14.
Loo PS, Thomas SC, Nicolson MC, et al. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 2010; 5: 442-447.
15.
Mukhopadhyay S, Katzenstein A-LA. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing ttf-1, napsin a, p63, and ck5/6. Am J Surg Pathol 2011; 35: 15-25.
16.
Kayser G, Csanadi A, Otto C, et al. Simultaneous multi-antibody staining in non-small cell lung cancer strengthens diagnostic accuracy especially in small tissue samples. PLOS One 2013; 8.
17.
Ordó¼ez NG. A word of caution regarding napsin a expression in squamous cell carcinomas of the lung. Am J Surg Pathol 2012; 36: 396-401.
18.
Marson VJ, Mazieres J, Groussard O, et al. Expression of ttf-1 and cytokeratins in primary and secondary epithelial lung tumours: Correlation with histological type and grade. Histopathology 2004; 45: 125-134.
19.
Tsuta K, Tanabe Y, Yoshida A, et al. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, s100a2, s100a7, and sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the lung. J Thorac Oncol 2011; 6: 1190-1199.
20.
Zhao W, Wang H, Peng Y, et al. Delta np63, ck5/6, ttf-1 and napsin a, a reliable panel to subtype non-small cell lung cancer in biopsy specimens. Int J Clin Exp Pathol 2014; 7: 4247-4253.
21.
Terry J, Leung S, Laskin J, et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010; 34: 1805-1811.
22.
Warth A, Muley T, Herpel E, et al. Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. Histopathology 2012; 61: 1017-1025.
23.
Pelosi G, Fraggetta F, Pasini F, et al. Immunoreactivity for thyroid transcription factor-1 in stage i non-small cell carcinomas of the lung. Am J Surg Pathol 2001; 25: 363-372.
24.
Hirano T, Gong YB, Yoshida K, et al. Usefulness of ta02 (napsin a) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma. Lung Cancer 2003; 41: 155-162.
25.
Ueno T, Linder S, Elmberger G. Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer 2003; 88: 1229-1233.
26.
Ezzat Nl-S, Tahoun N. The role of napsin-a and desmocollin-3 in classifying poorly differentiating non-small cell lung carcinoma. J Egypt Natl Canc Inst 2016; 28: 13-22.
27.
Turner BM, Cagle PT, Sainz IM, et al. Napsin a, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med 2012; 136: 163-171.
28.
Bishop JA, Teruya-Feldstein J, Westra WH, et al. P40 (delta np63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 2012; 25: 405-415.
29.
Tatsumori T, Tsuta K, Masai K, et al. P40 is the best marker for diagnosing pulmonary squamous cell carcinoma: Comparison with p63, cytokeratin 5/6, desmocollin-3, and sox2. Appl Immunohist Mol Morphol 2014; 22: 377-382.
30.
Ma Y, Fan M, Dai L, et al. Expression of p63 and ck5/6 in early-stage lung squamous cell carcinoma is not only an early diagnostic indicator but also correlates with a good prognosis. Thorac Cancer 2015; 6: 288-295.
31.
Fukuoka J, Dracheva T, Shih JH, et al. Desmoglein 3 as a prognostic factor in lung cancer. Hum Pathol 2007; 38: 276-283.
32.
Savci-Heijink CD, Kosari F, Aubry M-C, et al. The role of desmoglein-3 in the diagnosis of squamous cell carcinoma of the lung. Am J Pathol 2009; 174: 1629-1637.
33.
Gomez-Morales M, Camara-Pulido M, Teresa Miranda-Leon M, et al. Differential immunohistochemical localization of desmosomal plaque-related proteins in non-small-cell lung cancer. Histopathology 2013; 63: 103-113.
34.
Saaber F, Chen Y, Cui T, et al. Expression of desmogleins 1-3 and their clinical impacts on human lung cancer. Pathol Res Pract 2015; 211: 208-213.
35.
Barbareschi M, Cantaloni C, Del Vescovo V, et al. Heterogeneity of large cell carcinoma of the lung an immunophenotypic and mirna-based analysis. Am J Clin Pathol 2011; 136: 773-782.
36.
Rossi G, Mengoli MC, Cavazza A, et al. Large cell carcinoma of the lung: Clinically oriented classification integrating immunohistochemistry and molecular biology. Virch Arch 2014; 464: 61-68.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
